Effect of the location of previous atherosclerotic disease on prognosis in diabetic patients. The Barbanza diabetes study;Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-diabetes

Revista Espanola de Cardiologia

Volumn 61, Issue 11, 2008, Pages 1168-1177

  González Juanatey, José R ^a,e   Grigorian Shamagian, Lilian ^a   Juiz Crespo, María A ^b   Sánchez Loureiro, Manuel ^b   Rodríguez Moldes, Esperanza ^c   Dopico Pita, Jaime ^b   Gutiérrez Fernández, Genaro ^b   Torres Colomer, Jorge ^b   Blanco Rodríguez, Rubén ^b   Otero Raviña, Fernando ^d   Fernandez Villaverde J M ^f   Allut Vidal, G ^f   Dominguez Lopez J ^f   Gomez Vazquez J L ^f   Parga Garcia V ^f   De Blas Abad, P ^f   Pastor Benavent, C ^f   Fernandez Seoane A ^f   De La Fuente Marino R ^f   Maestro Saavedra, J ^f   Ramos Gonzalez A ^f   Alvear Garcia M J ^f   Perez Llamas M A ^f   Eiris Cambre M J ^f   Besada Gesto, R ^f   De Frutos de Marcos, C ^f   Caneda Villar, M C ^f   Santos Rodriguez J A ^f   Lado Lopez M ^f   Turrado Turrado, V ^f   Vaamonde Mosquera, L ^f   Lado Llerena, A ^f   Nores Lorenzo, A ^f   more..

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Centro de Salud   (Spain)

^c Centro de Salud Os Mallos   (Spain)

^d SERGAS   (Spain)

^e University Hospital of Santiago de Compostela   (Spain)

^f NONE

Author keywords

Atherothrombosis; Diabetes mellitus; Primary care; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROGNOSIS; PROSPECTIVE STUDY;

EID: 55849091723     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13127848     Document Type: Article

References (40)

1. González-Juanatey JR, Alegría-Ezquerra E, García-Acuña JM, González-Maqueda I, Lozano JV. Impacto de la diabetes en las enfermedades cardíacas en España. Estudio CARDIOTENS 1999. Med Clin (Barc). 2001;116:686-91.
2. González-Clemente JM, Palma S, Arroyo J, Vilardell C, Caixás A, Jiménez-Palop O, et al. ¿La diabetes mellitus es un equivalente de riesgo coronario? Resultados de un meataanálisis de estudios prospectivos. Rev Esp Cardiol. 2007;60:1167-76.
3. Hogan P, Dall T, Nikolov P. Economics costs of diabetes in the United States in 2002. Diabetes Care. 2003;26:917-32.
4. Castell C, Tresserras R, Serra J, Goday A, Lloveras G, Salleras L. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract. 1999;43:33-40.
5. De Pablos-Velasco PL, Martínez-Martín FJ, Rodríguez-Pérez F, Anía BJ, Losada A, Betancor P. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population - comparison of the 1997 ADA and the 1985 WHO criteria. The Guía Study. Diabet Med. 2001;18:235-41.
6. Soriguer-Escofet F, Esteva I, Rojo-Martínez G, Ruiz-de-Adana S, Catalá M, Merelo MJ, et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002;56:213-20.
7. Masiá R, Sala J, Rohlfs I, Piulats R, Manresa JM, Marrugat J. Prevalencia de diabetes mellitus en la provincia de Girona, España: el estudio REGICOR. Rev Esp Cardiol. 2004;57:261-4.
8. Valdés S, Rojo-Martínez G, Soriguer F. Evolución de la prevalencia de diabetes tipo 2 en población adulta española. Med Clin (Barc). 2007;129:352-5.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
10. Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
11. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-34.
12. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
13. Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin dependent diabetes mellitus. Ann Med. 1996;28:415-8.
14. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
15. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-31.
16. Laakso M. Hyperglicemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-42.
17. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modificable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
18. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol. 1988;128:116-23.
19. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-8.
20. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke. 1996;27:63-8.
21. Folsom AR, Rasmussen ML, Chambless LE, Howard G, Cooper LS, Schmidt MI, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care. 1999;22:1077-83.
22. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472-9.
23. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81.
24. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causesof death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:14-21.
25. Dale AC, Nilsen TI, Vatten L, Midthjell K, Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74914 individuals in the HUNT 1 Study. Eur Heart J. 2007;28:2924-9.
26. Manzano L, Mostaza JM, Suárez C, Cairols M, Redondo R, Valdivielso P, et al. Modificación de la estratificación del riesgo vascular tras la determinación del índice tobillo-brazo en pacientes sin enfermedad arterial conocida. Estudio MERITO. Med Clin (Barc). 2007;128:241-6.
27. Manzano L, García-Díaz JD, Gómez-Cerezo J, Mateos J, Del Valle FJ, Medina-Asensio J, et al. Valor de la determinación del índice tobillo-brazo en pacientes de riesgo vascular sin enfermedad aterotrombótica conocida: estudio VITAMIN. Rev Esp Cardiol. 2006;59:647-9.
28. González-Juanatey JR, Mazón-Ramos P, Allut-Vidal G, Pérez-Llamas M, Blanco-Rodríguez R, Pastor-Benavent MC, et al. Control of vascular and renal risk factors in diabetic patients. Results of the Barbanza Diabetes Eductional Programme. Eur J Gen Pract. 2004;10:109-10.
29. Expert Committee on the Diagnosis and Clasification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care. 2002;25 Suppl 1:1-147.
30. Muñiz J, López-Rodríguez I, Gabriel-Sánchez R, Juane R, Montiel-Carracedo MD, López-Quintela A, et al. Evidencia de presiones arteriales más elevadas en niños y adolescentes del interior rural de Galicia que en otras localizaciones en España. Rev Esp Cardiol. 1998;51:823-31.
31. Gorter PM, Visseren FLJ, Algra A, van der Graaf Y. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study. Diabet Med. 2007;24:1352-60.
32. Becker A, Bos G, De Vegt F, Kostense PJ, Dekker JM, Nijpels G, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J. 2003;24:1406-13.
33. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;9 Suppl C:3-74.
34. American Diabetes Association. Clinical Practice Recommendations 2007. Diabetes Care. 2007;30 Suppl 1:1-103.
35. Steg PG, Bhatt DL, Wilson PWF, D'Agostino R, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197-206.
36. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.
37. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria en type 2 diabetes. N Engl J Med. 2004;351:1941-51.
38. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
39. Parving HH, Lehner H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
40. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.